Capricor Therapeutics Reports Topline Results from Phase II Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

Capricor Therapeutics announced that its Phase II INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19 met its primary objective of safety.